OBJECTIVES: This study was designed to assess sociodemographic and medical insurer factors associated with receipt of highly active antiretroviral therapy (HAART). METHODS: Patients included (n = 959) were enrolled in the Johns Hopkins HIV Clinic after April 1, 1996, received > or = 90 days of care, and had a CD4 count > or = 500 cells/mm3 or HIV-1 RNA > 20 000 copies/mL. We assessed the associations of sociodemographic factors and medical insurance with receipt of HAART, stratified by 2 time periods (April 1996 through March 1997 versus April 1997 through March 1999). RESULTS: HAART was more likely to be used in patients who were > 39 years, White, had CD4 counts < 350 cells/mm3, had fewer missed clinic visits, and did not have intravenous drug use as their risk factor for HIV transmission. In period 1 (April 1996 through March 1997), HAART was more likely to be used in patients who were commercially insured than in other payer groups; differences between payers narrowed in period 2 (April 1997 through March 1999), however, as did differences by race. CONCLUSIONS: Differences in use of HAART on the basis of payer have narrowed since 1996. This encouraging finding may demonstrate the importance of programs that lower economic barriers to medical care.
OBJECTIVES: This study was designed to assess sociodemographic and medical insurer factors associated with receipt of highly active antiretroviral therapy (HAART). METHODS:Patients included (n = 959) were enrolled in the Johns Hopkins HIV Clinic after April 1, 1996, received > or = 90 days of care, and had a CD4 count > or = 500 cells/mm3 or HIV-1 RNA > 20 000 copies/mL. We assessed the associations of sociodemographic factors and medical insurance with receipt of HAART, stratified by 2 time periods (April 1996 through March 1997 versus April 1997 through March 1999). RESULTS: HAART was more likely to be used in patients who were > 39 years, White, had CD4 counts < 350 cells/mm3, had fewer missed clinic visits, and did not have intravenous drug use as their risk factor for HIV transmission. In period 1 (April 1996 through March 1997), HAART was more likely to be used in patients who were commercially insured than in other payer groups; differences between payers narrowed in period 2 (April 1997 through March 1999), however, as did differences by race. CONCLUSIONS: Differences in use of HAART on the basis of payer have narrowed since 1996. This encouraging finding may demonstrate the importance of programs that lower economic barriers to medical care.
Authors: C C Carpenter; M A Fischl; S M Hammer; M S Hirsch; D M Jacobsen; D A Katzenstein; J S Montaner; D D Richman; M S Saag; R T Schooley; M A Thompson; S Vella; P G Yeni; P A Volberding Journal: JAMA Date: 1997-06-25 Impact factor: 56.272
Authors: A J Davidson; S L Bertram; D C Lezotte; W M Marine; C A Rietmeijer; B B Hagglund; D L Cohn Journal: Med Care Date: 1998-12 Impact factor: 2.983
Authors: M F Shapiro; S C Morton; D F McCaffrey; J W Senterfitt; J A Fleishman; J F Perlman; L A Athey; J W Keesey; D P Goldman; S H Berry; S A Bozzette Journal: JAMA Date: 1999 Jun 23-30 Impact factor: 56.272
Authors: M D Stein; J Piette; V Mor; T J Wachtel; J Fleishman; K H Mayer; C C Carpenter Journal: J Gen Intern Med Date: 1991 Jan-Feb Impact factor: 5.128
Authors: Michael J Mugavero; K Rivet Amico; Andrew O Westfall; Heidi M Crane; Anne Zinski; James H Willig; Julia C Dombrowski; Wynne E Norton; James L Raper; Mari M Kitahata; Michael S Saag Journal: J Acquir Immune Defic Syndr Date: 2012-01-01 Impact factor: 3.731
Authors: Allison L Agwu; John A Fleishman; P Todd Korthuis; George K Siberry; Jonathan M Ellen; Aditya H Gaur; Richard Rutstein; Kelly A Gebo Journal: J Acquir Immune Defic Syndr Date: 2011-09-01 Impact factor: 3.731
Authors: Anne Zinski; Andrew O Westfall; Lytt I Gardner; Thomas P Giordano; Tracey E Wilson; Mari-Lynn Drainoni; Jeanne C Keruly; Allan E Rodriguez; Faye Malitz; D Scott Batey; Michael J Mugavero Journal: Am J Public Health Date: 2015-08-13 Impact factor: 9.308
Authors: Kristen Clements-Nolle; Rani Marx; Michael Pendo; Eileen Loughran; Milton Estes; Mitchell Katz Journal: Am J Public Health Date: 2008-02-28 Impact factor: 9.308
Authors: Yue Pan; Lisa R Metsch; Lauren K Gooden; Morgan M Philbin; Eric S Daar; Antoine Douaihy; Petra Jacobs; Carlos Del Rio; Allan E Rodriguez; Daniel J Feaster Journal: Int J STD AIDS Date: 2019-06-03 Impact factor: 1.359
Authors: Michael J Mugavero; Hui-Yi Lin; James H Willig; Andrew O Westfall; Kimberly B Ulett; Justin S Routman; Sarah Abroms; James L Raper; Michael S Saag; Jeroan J Allison Journal: Clin Infect Dis Date: 2009-01-15 Impact factor: 9.079
Authors: Michael J Mugavero; Hui-Yi Lin; Jeroan J Allison; Thomas P Giordano; James H Willig; James L Raper; Nelda P Wray; Stephen R Cole; Joseph E Schumacher; Susan Davies; Michael S Saag Journal: J Acquir Immune Defic Syndr Date: 2009-01-01 Impact factor: 3.731
Authors: Annette L Fitzpatrick; Neil R Powe; Lawton S Cooper; Diane G Ives; John A Robbins Journal: Am J Public Health Date: 2004-10 Impact factor: 9.308